Products
  1. Home
  2. Products
  3. Inhibitors & Activators for IBD Research
Products
Inquiry

* Please note that all of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Tivozanib

Cat. No.: IBDI-436277

Tivozanib (AV-951; KRN951) is a selective and orally active VEGFR tyrosine kinase inhibitor with IC50 of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib has the potential for the research of metastatic renal cell carcinoma (RCC) .

Size (Solution): 10 mM * 1 mL in DMSO

Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution

Size (Solid):

Product Details

Target VEGFR
Molecular Weight 454.86
Appearance Solid
Synonyms AV-951, KRN951
SMILES O=C(NC1=CC=C(C=C1Cl)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC4=NOC(C)=C4
Purity 99.37%

Storage & Handling

Shipping Room temperature in continental US. May vary elsewhere.
Storage Powder: -20°C/3 years; 4°C/2 years
In solvent: -80°C/6 months; -20°C/1 month
Regulatory Status This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.
! For research use only, not intended for any clinical use.
Copyright © Ace Therapeutics. All rights reserved.